Additional file 1 of Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
- Resource Type
- Authors
- Chen, Xinhua; Wang, Wei; Chen, Xinghui; Wu, Qianhui; Sun, Ruijia; Ge, Shijia; Zheng, Nan; Lu, Wanying; Yang, Juan; Rodewald, Lance; Yu, Hongjie
- Source
- Subject
- Language
Additional file 1: Table S1. Baseline demographic characteristics for the study population. Table S2. Comparison of SARS-CoV-2 neutralizing antibody levels between adults, 18-59 years of age and elderly adults, 60 years and older. Table S3. Neutralizing antibody dynamics for CoronaVac by time period. Table S4. Search terms for the three peer-reviewed databases and two preprint servers. Table S5. Inclusion and exclusion criteria for systematic review. Table S6. Summary of neutralizing antibody levels over time by different vaccines. Table S7. Comparison of neutralization assays used in homologous prime-boost studies and in phase I/II clinical trials for convalescent sera. Table S8. Fold-changes of neutralization antibody levels against the Delta variant compared to the prototype strain. Figure S1. Times of blood sample collection. Figure S2. CoronaVac vaccine-induced SARS-CoV-2 antibody titers and seroprevalence by age group and dose number. Figure S3. Fitted profiles for CoronaVac vaccine-induced SARS-CoV-2 antibody titers and seroprevalence by age after the first and second doses. Figure S4. Dynamic patterns of CoronaVac vaccine-induced SARS-CoV-2 antibody titers and corresponding seroprevalences after the first and second doses on days 0 and 28. Figure S5. Loss of protective immunity acquired from two doses of CoronaVac vaccine. Figure S6. Predicted CoronaVac vaccine-induced neutralizing antibody titers against the Delta SARS-CoV-2 variant in vaccine recipients, assuming 2.4-fold reduction of antibody levels against the Delta SARS-CoV-2 variant compared to the prototype SARS-CoV-2 strain. Figure S7. Flowchart of inclusion of retrieved studies. Figure S8. Predicting efficacy over time across different vaccines and clinical endpoints for other VOCs. Figure S9. Sensitivity analysis of predicted efficacy changing fold-change parameter for mRNA-1273. Figure S10. Sensitivity analysis of predicted efficacy by using upper limit of model parameter slope (k). Figure S11. Sensitivity analysis of predicted efficacy by using lower limit of model parameter slope (k).